Evidence map›Paper›PMID 39908986›Full record

ReviewCell metabolism2025

The emerging role of dysregulated propionate metabolism and methylmalonic acid in metabolic disease, aging, and cancer.

Moniquetta Shafer, Vivien Low, Zhongchi Li, John Blenis

Abstract readReview
In one paragraph

Review in Cell metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Nutrients · 2026
    Trial
  2. Propionate promotes CD8Journal for immunotherapy of cancer · 2026
    Article
  3. Article
  4. Article
  5. Catalyzing MRI: An Enzymatic Strategy forChemical & biomedical imaging · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. [Occurrence status and treatment strategies of abnormal growth and development in children with methylmalonic acidemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Moniquetta ShaferDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Vivien LowCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zhongchi LiDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. Electronic address: zhl4003@med.cornell.edu.
John BlenisDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. Electronic address: job2064@med.cornell.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
SIGNAL TRANSDUCTION TO PP70 S6KR01GM051405 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLENIS, JOHN · 1995 to 2023
$14.0M
ONCOGENIC REGULATION OF S6 PROTEIN KINASE &CELL GROWTHR01CA046595 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI JOHN BLENIS · 1988 to 2026
$10.6M
Predoctoral Training in Pharmacological SciencesT32GM141949 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Kristen Elizabeth Pleil · 2021 to 2026
$2.5M
Propionate metabolism and cancerR01CA273357 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI JOHN BLENIS · 2023 to 2026
$2.5M
Investigating the link between propionate metabolism and agingK99AG084860 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI LI, ZHONGCHI · 2024 to 2025
$204k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA046595NCI NIH HHS R01 CA273357NIA NIH HHS K99 AG084860NIGMS NIH HHS R01 GM051405NIGMS NIH HHS T32 GM141949
6 · The paper itself

Abstract

Propionate metabolism dysregulation has emerged as a source of metabolic health alterations linked to aging, cardiovascular and renal diseases, obesity and diabetes, and cancer. This is supported by several large cohort population studies and recent work revealing its role in cancer progression. Mutations in several enzymes of this metabolic pathway are associated with devastating inborn errors of metabolism, resulting in severe methylmalonic and propionic acidemias. Beyond these rare diseases, however, the broader pathological significance of propionate metabolism and its metabolites has been largely overlooked. Here, we summarize earlier studies and new evidence that the alteration of this pathway and associated metabolites are involved in the development of various metabolic diseases and link aging to cancer progression and metastasis.

Indexed as

AgingMetabolic DiseasesMethylmalonic AcidNeoplasmsPropionatesAnimalsHumansMethylmalonic AcidPropionatesagingBCAA metabolismBCAAsbranched-chain amino acidscancer metabolismmetabolic disordersmethylmalonic acidmethylmalonyl-CoAMMApropionatepropionyl-CoA

Identifiers

PMID39908986
PMCPMC11984558

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.